Table 1:
Baseline patient and disease characteristics
| EZH2mut (n=45) | EZH2WT (n=54) | |
|---|---|---|
| Age, years | 62 (57–68) | 61 (53–67) |
| Sex | ||
| Male | 19 (42%) | 34 (63%) |
| Female | 26 (58%) | 20 (37%) |
| ECOG performance status | ||
| 0 | 21 (47%) | 26 (48%) |
| 1 | 24 (53%) | 23 (43%) |
| 2 | 0 | 4 (7%) |
| Missing | 0 | 1 (2%) |
| Satisfied GELF criteria* | ||
| Yes | 31 (69%) | 40 (74%) |
| No | 14 (31%) | 14 (26%) |
| Time from initial diagnosis, years | 4·7 (1·7–6·4) | 6·3 (3·4–9·0) |
| Histology | ||
| Grade 1, 2, or 3a | 42 (93%) | 51 (94%)† |
| Grade 3b or transformed follicular lymphoma‡ | 3 (7%) | 6 (11%)† |
| Previous lines of anticancer therapy§ | ||
| One | 2 (4%) | 1 (2%) |
| Two | 22 (49%) | 16 (30%) |
| Three | 10 (22%) | 11 (20%) |
| Four | 4 (9%) | 10 (19%) |
| Five or more | 7 (16%) | 16 (30%) |
| Median | 2 (2–43) | 3 (2–5) |
| Refractory to last regimen¶ | 22 (49%) | 22 (41%) |
| Poor risk features | ||
| Refractory to a rituximab-containing regimen|| | 22 (49%) | 32 (59%) |
| Double refractory** | 9 (20%) | 15 (28%) |
| Previous haematopoietic stem-cell transplant | 4 (9%) | 21 (39%) |
| Disease progression within 24 months of disease diagnosis in patients treated with first-line immunochemotherapy (POD24) | 19 (42%) | 32 (59%) |
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. GELF=Groupe d’Etude des Lymphomes Folliculaires.
Defined as a target lesion of more than 7 cm in diameter, three nodal target lesions of more than 3 cm in diameter each, the presence of B symptoms at baseline, a concentration of serum lactate dehydrogenase higher than the upper limit of normal, a serum haemoglobin concentration of 100 g/L or less, a neutrophil count of 1500 cells per µL or less, or a platelet count of 100 000 platelets per mL or less.
Some patients were counted in more than one category.
Patients with confirmed grade 3b or transformed follicular lymphoma following a central pathology review.
Excludes maintenance, consolidation, adjuvant, and neoadjuvant therapies when counted as their own line.
Patients with stable disease or progressive disease to the most recent previous anticancer therapy.
Refractory to either rituximab monotherapy or rituximab-containing therapy or progressive disease within 6 months of completion of rituximab-containing therapy.
Refractory to rituximab (as a monotherapy or as part of a combination therapy) and a chemotherapy induction regimen containing one or more alkylating agent or purine nucleoside antagonist and have relapsed within 6 months.